IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Bioxcel Therapeutics Inc (BTAI)

CUSIP: 09075P204 | NYSE | Healthcare · Drug Manufacturers - Specialty & Generic | Micro Cap | 71 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13G/AArmistice Capital, LLC1,621,7165.0%Newly reportedJun 30, 2026No 13F filer matched
13G/AArmistice Capital, LLC1,621,716
5.0% of class · Jun 30, 2026

Institutional Holders — Q3 2026

Farther Finance Advisors, LLC25
0.0% of portfolio›$1
IFP Advisors, Inc13
0.0% of portfolio›$1
Barclays PLC1
0.0% of portfolio›$0
StyleTurnoverLocationFiled
Farther Finance Advisors, LLC
25$10.0%IndexLowSan Francisco, CA2026-10-08
IFP Advisors, Inc
13$10.0%CoreLowTampa, FL2026-10-16
Barclays PLC
1$00.0%GrowthMediumLondon, United Kingdom2026-11-06
Newly reported
No 13F filer matched